←Back to Expert Scholars
Translational Medicine / 转化医学ADC Lineage Targets
Jan Cosaert
MD
🏢ADC Therapeutics🌐Switzerland
Chief Medical Officer
20
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Jan Cosaert has led clinical development of antibody drug conjugates targeting hematologic malignancies including CD19 directed loncastuximab tesirine. His work advances lineage targeting ADCs in lymphoma and other blood cancers. He combines regulatory and clinical expertise to bring ADCs to patients.
Share:
🧪Research Fields 研究领域
antibody drug conjugates
hematologic malignancies
CD19
loncastuximab
clinical development
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Jan Cosaert 的研究动态
Follow Jan Cosaert's research updates
留下邮箱，当我们发布与 Jan Cosaert（ADC Therapeutics）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment